India  

ADMP's Symjepi Hits Walgreen's Shelves, LLY's Antibody Cuts COVID-19 Risk By 80%, FLDM On Watch

RTTNews Friday, 22 January 2021
Today's Daily Dose brings you news about the effectiveness of Lilly's Bamlanivimab in reducing the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, executive changes at BiondVax Pharma, regulatory update on Genetic Technologies' COVID-19 PRS Test, Adamis' SYMJEPI products being made available in the Walgreens Prescription Savings Club, to name a few.
0
shares
ShareTweetSavePostSend
 

You Might Like


Related videos from verified sources

Pfizer’s COVID-19 Vaccine May Be Less Effective in Obese People, Study Says [Video]

Pfizer’s COVID-19 Vaccine May Be Less Effective in Obese People, Study Says

Pfizer’s COVID-19 Vaccine May Be Less Effective in Obese People, Study Says. Researchers in Italy have discovered that the Pfizer/BioNTech vaccine may be less effective in obese individuals...

Credit: Wibbitz Top Stories     Duration: 01:13Published
High risk individuals who test positive for COVID may be eligible for monoclonal antibody treatment [Video]

High risk individuals who test positive for COVID may be eligible for monoclonal antibody treatment

High risk individuals who test positive for COVID may be eligible for monoclonal antibody treatment

Credit: ABC 2 News WMAR     Duration: 04:41Published